INDIUM IN-111 CHLORIDE - Generic Drug Details

« Back to Dashboard

What are the generic sources for indium in-111 chloride and what is the scope of patent protection?

Indium in-111 chloride is the generic ingredient in two branded drugs marketed by Ge Healthcare and Curium, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for INDIUM IN-111 CHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	3
DailyMed Link:	INDIUM IN-111 CHLORIDE at DailyMed

US Patents and Regulatory Information for INDIUM IN-111 CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	INDICLOR	indium in-111 chloride	INJECTABLE;INJECTION	019862-001	Dec 29, 1992		DISCN	Yes	No
Curium	INDIUM IN 111 CHLORIDE	indium in-111 chloride	INJECTABLE;INJECTION	019841-001	Sep 27, 1994		DISCN	Yes	No

Indium In-111 Chloride Market Dynamics, Patent Position, FDA Status, and Financial Outlook

Last updated: September 3, 2026

Indium In-111 chloride is a low-volume radiopharmaceutical precursor used to label diagnostic agents rather than a major standalone therapeutic product. Its commercial value is tied to radiolabeled products such as indium In-111 pentetreotide and indium In-111 oxyquinoline, hospital nuclear-medicine procedures, cyclotron and isotope logistics, and the availability of competing radionuclides such as gallium-68 and fluorine-18.

Public companies do not generally report revenue for indium In-111 chloride separately. The product is sold through specialized radiopharmaceutical channels, and financial exposure is usually embedded in broader nuclear-medicine, diagnostic-imaging, or isotope businesses. The long-term outlook is stable to declining for traditional In-111 applications, with selective demand sustained by established imaging protocols, supply-chain reliability, and clinical sites that lack newer PET infrastructure.

What is indium In-111 chloride used for?

Indium In-111 chloride is a sterile radioactive solution containing indium-111 chloride. It is primarily a radiolabeling material used to attach indium-111 to pharmaceutical chelators, peptides, antibodies, or white blood cells.

Indium-111 has several technical characteristics that determine its market position:

Attribute	Commercial relevance
Radionuclide	Indium-111
Physical half-life	Approximately 67 hours
Radiation type	Gamma emission suitable for SPECT imaging
Main use	Radiolabeling diagnostic compounds
Typical supply model	Patient-specific or scheduled radiopharmacy production
Primary customers	Hospitals, radiopharmacies, imaging centers, drug manufacturers
Main alternatives	Gallium-68, fluorine-18, technetium-99m
Product category	Diagnostic radiopharmaceutical precursor

The chloride solution normally is not the complete diagnostic product. It is combined with a ligand or drug substance under controlled conditions. The resulting labeled product is administered to the patient.

Historical and current applications include:

• Indium In-111 pentetreotide for somatostatin-receptor imaging.
• Indium In-111 oxyquinoline for labeling leukocytes.
• Research and specialized diagnostic agents involving antibodies, peptides, and cellular components.
• Certain hospital radiopharmacy procedures where SPECT remains clinically and operationally available.

The product’s commercial importance therefore depends on downstream radiolabeling demand rather than on direct prescribing volume.

What is the FDA regulatory status of indium In-111 chloride?

Indium In-111 chloride is regulated as a radioactive diagnostic drug and radiolabeling component. FDA-approved product labeling identifies the solution for radiolabeling suitable pharmaceutical preparations for diagnostic use. The regulatory controls cover radioactive content, sterility, chemical purity, radionuclidic identity, expiration dating, and handling requirements.

The FDA framework creates several commercial barriers:

1. A manufacturer must comply with drug-current-good-manufacturing-practice requirements.
2. Radioactive materials must be produced, transported, and handled under applicable Nuclear Regulatory Commission or Agreement State requirements.
3. Production must meet radionuclide purity and activity specifications.
4. Distribution must account for the approximately 67-hour half-life.
5. The labeled final product may require separate FDA approval or an approved compounding and radiopharmacy pathway.

Indium In-111 chloride should not be analyzed in the same way as an ordinary small-molecule tablet. Its regulatory value is linked to radioactive production, short shelf life, validated labeling procedures, and the approval status of the final radiopharmaceutical.

What is the Orange Book status of indium In-111 chloride?

The Orange Book is not a complete map of the commercial protection surrounding indium In-111 chloride. The relevant product may appear as an approved radioactive injection or radiolabeling solution, but the meaningful commercial protection historically has been concentrated in the labeled diagnostic agent, kit, formulation, or method of use.

The principal patent conclusions are:

• Indium-111 itself is an established radionuclide and is not subject to meaningful composition-of-matter exclusivity.
• Indium In-111 chloride is a simple inorganic radioactive salt with limited patentability as a basic chemical entity.
• Historic patents covering indium-labeled peptides, chelators, antibodies, imaging methods, and kit formulations are generally old and, in many cases, expired.
• Any current protection is more likely to involve manufacturing controls, proprietary kits, device integration, or specific radiolabeled compounds than the chloride precursor itself.
• FDA regulatory exclusivity for older indium-labeled diagnostic products is generally no longer a major barrier.

A product-by-product Orange Book review is required because the chloride solution, radiolabeling kit, and finished imaging agent can have separate regulatory records.

What patents protect indium In-111 chloride?

The patent estate for indium In-111 chloride is weak as a standalone pharmaceutical estate. The commercially important rights historically have covered downstream technologies.

Potential patent categories

Patent category	Relevance to indium In-111 chloride	Current risk profile
Indium-111 chloride composition	Limited	Very low
Radionuclide production	Moderate	Process-dependent
Chelator chemistry	Moderate to high historically	Mostly mature
Peptide or antibody conjugates	High for specific products	Product-specific
Radiolabeling kits	Moderate	Depends on formulation and claims
Imaging methods	Moderate historically	Many older rights expired
Leukocyte-labeling methods	Low to moderate	Mature technology
Manufacturing and quality systems	Commercially important	Often protected as know-how rather than patents

Patent barriers are more likely to arise from proprietary chelators, labeling conditions, kit stability, or a specific peptide sequence than from the chloride solution. Trade secrets and operational know-how can also have greater practical value than patents because radiopharmacies must consistently achieve high labeling yields and acceptable sterility within a short production window.

When does indium In-111 chloride lose exclusivity?

Indium In-111 chloride does not have a meaningful future loss-of-exclusivity event comparable to a blockbuster small molecule. Its underlying chemistry and radionuclide are mature. Market entry depends on FDA approval, radioactive-material licensing, manufacturing capability, and distribution economics.

The relevant exclusivity timeline is:

Milestone	Commercial effect
Historical approval of indium-111 chloride products	Established the regulated supply category
Expiration of downstream peptide and kit patents	Opened competition in mature labeled products
Entry of alternative radiopharmaceuticals	Reduced dependence on In-111
Expansion of PET infrastructure	Increased substitution pressure
Current market	Supply, service, and quality differentiate vendors more than patents

There is no clear evidence that an unexpired patent covering the basic indium In-111 chloride solution is the principal market barrier. Generic-style competition remains constrained by radioactive manufacturing and distribution rather than by ordinary pharmaceutical patent litigation.

Are there Paragraph IV challenges to indium In-111 chloride?

Paragraph IV litigation is not a central feature of this market. A traditional Paragraph IV challenge usually involves an abbreviated new drug application asserting that listed patents are invalid, unenforceable, or not infringed. Indium In-111 chloride has limited exposure to this framework because:

• The product is a radioactive diagnostic solution rather than a high-volume oral drug.
• The most relevant patents historically covered downstream labeled agents.
• Several established products and methods are mature.
• Manufacturing and radioactive logistics are difficult to replicate at scale.
• The market is too small to support extensive Hatch-Waxman litigation in many cases.

A challenger could still contest listed patents associated with a finished radiolabeled product, but the expected commercial payoff is materially lower than for a large therapeutic drug.

No major, widely reported current Paragraph IV campaign directed specifically at the basic indium In-111 chloride precursor is identified in the principal public regulatory and litigation records cited here.

What formulation patents protect indium In-111 chloride?

Formulation protection is narrower than in conventional injectable drugs. The key technical requirements are stability, sterility, radionuclidic purity, chemical purity, and compatibility with the downstream ligand or kit.

Potential formulation claims may address:

• Acidic or buffered aqueous solutions.
• Carrier concentrations and excipients.
• Container-closure systems.
• Sterile filtration and aseptic filling.
• Radioactive concentration and calibration.
• Shelf-life management.
• Compatibility with peptide or antibody labeling kits.
• Residual metal control and radiochemical purity.

The commercial value of such claims is limited by the product’s short half-life. A formulation that improves chemical stability but does not materially improve labeling performance, shipping radius, or usable shelf life may have limited economic impact.

How is indium In-111 chloride manufactured and supplied?

Indium-111 is commonly produced through charged-particle irradiation of enriched cadmium targets, followed by chemical separation and purification. The production chain requires specialized cyclotron capacity, target material, radiochemical processing, quality-control testing, and licensed distribution.

The supply model has several economic constraints:

• The isotope decays continuously during production and transport.
• Orders must be scheduled around clinical procedures.
• Geographic distribution radius is limited.
• Production interruptions can create immediate hospital shortages.
• Enriched target material and specialized processing add cost.
• A manufacturer must maintain radioactive-material licenses and validated facilities.

These factors create manufacturing barriers without requiring strong patent protection. A new entrant needs more than an FDA filing. It needs qualified isotope production, reliable logistics, radiopharmacy relationships, and sufficient recurring demand to keep the production system economically viable.

How does indium In-111 chloride compare with gallium-68 and fluorine-18?

Gallium-68 and fluorine-18 are the principal technology pressures on traditional indium-111 imaging.

Factor	Indium-111	Gallium-68	Fluorine-18
Imaging platform	SPECT	PET	PET
Half-life	About 67 hours	About 68 minutes	About 110 minutes for F-18
Distribution	More flexible than short-lived PET isotopes	Increasingly generator- and cyclotron-based	Requires regional production and distribution
Image resolution	Lower than PET	Higher than SPECT	Higher than SPECT
Typical use	Established peptide, cell, and antibody imaging	Modern receptor-targeted PET	Broad oncology and neurology applications
Market trend	Mature to declining	Expanding	Expanding
Infrastructure requirement	SPECT and radiopharmacy	PET and generator/cyclotron access	PET and production network

Indium-111 retains advantages where longer physical half-life, established SPECT equipment, or delayed biological imaging is important. Its disadvantages include lower image resolution, longer time to imaging, and a clinical shift toward PET.

The competitive threat is strongest in somatostatin-receptor imaging. Gallium-68-labeled agents have gained clinical preference in many settings because PET can provide higher sensitivity and resolution. Indium-111 remains relevant in sites without PET access and in applications where its physical half-life supports delayed imaging or cell-tracking protocols.

What is the financial trajectory of indium In-111 chloride?

Standalone revenue data are generally unavailable because suppliers report the product within broader nuclear-medicine operations. The financial trajectory can be summarized as mature and operationally resilient, but structurally pressured.

Revenue drivers

Demand is supported by:

• Existing SPECT infrastructure.
• Hospital protocols for indium-labeled leukocytes.
• Ongoing use of legacy indium-111 peptide imaging.
• Radiopharmacy customers that value predictable supply.
• Clinical applications where longer half-life is useful.
• International markets with slower PET adoption.

Revenue pressures

Demand is constrained by:

• Substitution by gallium-68 PET.
• Greater adoption of fluorine-18 imaging.
• Discontinuation or reduced use of older indium-labeled products.
• Limited procedure growth for mature SPECT indications.
• Radioactive decay and distribution losses.
• Small order sizes and scheduling complexity.
• High quality-control and licensing costs.

The likely financial path is not a sharp patent cliff. It is gradual volume erosion in traditional applications, partially offset by pricing, supply reliability, and continuing niche demand. Gross margins may remain defensible for established suppliers because manufacturing and licensing barriers limit the number of credible competitors.

Which companies compete in the indium-111 supply chain?

Competition is distributed across isotope producers, radiopharmaceutical manufacturers, hospital radiopharmacies, and diagnostic-drug companies. Relevant industry participants have included:

• Curium, a major global nuclear-medicine supplier.
• Jubilant Radiopharma and related radiopharmaceutical operations.
• Cardinal Health nuclear and radiopharmacy services.
• GE HealthCare pharmaceutical diagnostics.
• Regional hospital radiopharmacies.
• Cyclotron operators and contract radiopharmaceutical manufacturers.

The competitive basis is operational rather than primarily patent-based. Key differentiators include production uptime, regulatory compliance, geographic coverage, delivery reliability, customer service, and the ability to provide complete radiolabeling or finished-dose services.

What generic launch risks exist for indium In-111 chloride?

Generic launch risk is moderate in regulatory terms but limited in commercial terms.

A technically compliant entrant could face:

1. Low market volume.
2. High fixed costs for isotope production and quality control.
3. Short product dating.
4. Limited delivery radius.
5. Established customer contracts.
6. Competition from alternative radionuclides.
7. Dependence on downstream products that may have separate approvals.
8. Difficulty achieving attractive plant utilization.

The greatest risk to incumbent revenue is not a conventional generic launch. It is substitution by PET-based radiopharmaceuticals and changes in hospital imaging protocols.

What litigation and settlement issues affect the market?

The market has limited public litigation activity focused specifically on indium In-111 chloride. Patent disputes are more likely to involve:

• A finished radiolabeled peptide.
• A chelator or conjugate.
• A diagnostic method.
• A kit composition.
• A competing radiopharmaceutical platform.
• Regulatory exclusivity for a downstream product.

Settlement agreements, where they exist, may govern finished radiopharmaceutical products rather than the isotope precursor. No major settlement structure appears to create a durable market exclusion for the basic chloride solution.

How strong is the patent estate for indium In-111 chloride?

The standalone patent estate is weak. The practical competitive moat is stronger than the patent estate because of:

• Licensed radioactive production.
• Specialized facilities.
• Quality-control requirements.
• Short shelf life.
• Supply-chain coordination.
• Hospital and radiopharmacy relationships.
• Experience with validated radiolabeling procedures.

For investors and licensing teams, the product should be valued as a regulated isotope-service business rather than as a conventional patented drug asset.

Key Takeaways

• Indium In-111 chloride is principally a radiolabeling precursor, not a major standalone therapeutic product.
• Public standalone revenue is generally not disclosed.
• Its patent protection is limited; downstream labeled agents and kit technologies historically carried more relevant rights.
• Paragraph IV litigation and biosimilar competition are not central risks.
• Gallium-68 and fluorine-18 create the strongest long-term substitution pressure.
• Existing SPECT infrastructure, longer half-life, and specialized applications support residual demand.
• Manufacturing, radioactive licensing, quality control, and logistics are more important barriers than patents.
• The expected financial trajectory is mature and gradually declining, with pricing and supply reliability moderating volume pressure.
• The principal commercial risk is clinical substitution, not a sudden generic patent cliff.

FAQs About Indium In-111 Chloride

Is indium In-111 chloride administered directly to patients?

Usually no. It is primarily used to radiolabel a peptide, antibody, cellular product, or other pharmaceutical preparation before administration.

Is indium In-111 chloride a therapeutic radiopharmaceutical?

No. It is mainly associated with diagnostic imaging and radiolabeling. Therapeutic applications generally use different radionuclides, such as lutetium-177, yttrium-90, or actinium-225.

Does indium In-111 chloride have biosimilar competition?

No. Biosimilar rules apply to biological products. Indium In-111 chloride is an inorganic radioactive solution and is not a biologic.

Why does indium-111 remain commercially relevant despite PET competition?

Its approximately 67-hour half-life supports delayed imaging and broader transport windows. It also remains compatible with established SPECT systems and clinical protocols.

Is the main investment risk patent expiration?

No. The larger investment risk is declining procedure volume caused by migration from indium-111 SPECT imaging to gallium-68 or fluorine-18 PET imaging.

References

1. U.S. Food and Drug Administration. (n.d.). Indium In-111 chloride injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

3. International Atomic Energy Agency. (2019). Cyclotron produced radionuclides: Physical characteristics and production methods. IAEA.

4. National Council on Radiation Protection and Measurements. (2019). Radiation protection in medicine and nuclear medicine practice. NCRP.

5. Society of Nuclear Medicine and Molecular Imaging. (n.d.). Appropriate use and clinical guidance for nuclear medicine imaging. SNMMI.

6. U.S. Nuclear Regulatory Commission. (n.d.). Medical use of byproduct material. NRC.

7. Curium. (2023). Nuclear medicine diagnostic products and radiopharmaceutical services. Curium.

8. GE HealthCare. (2023). Annual report 2023. GE HealthCare.

9. Cardinal Health. (2023). Annual report 2023. Cardinal Health.